泰錦控股(08321.HK)擬"5合1"進行股份合併
格隆匯6月4日丨泰錦控股(08321.HK)公佈,董事會擬向股東提呈股份合併建議,當中涉及將每5股每股面值0.01港元的已發行及未發行現有股份合併為1股每股面值0.05港元的合併股份。
於公告日期,公司的法定股本為2000萬港元,分為20億股每股面值0.01港元的現有股份,其中8億股現有股份已以繳足或入賬列作繳足方式發行。緊隨股份合併生效後,假設自公告日期至股東特別大會日期不會發行或購回其他股份,則公司的法定股本將變更為2000萬港元,分為4億股每股面值0.05港元的合併股份,其中1.60億股已繳足或入賬列作繳足的合併股份將予發行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.